LEaH-Trial

Morbus Hodgkin

Registry

Cure and survival rates for Hodgkin's disease are over 90 percent and have previously been high. However, the long-term toxicities of the therapies that are usual from 25 to 30 years ago are numerous and sometimes serious, so that survival was and is associated with a reduction in quality of life for some patients. This is mainly due to the traditional extensive use of radiotherapy. But chemotherapy also caused long-term effects due to high cumulative doses of some very effective but toxic drugs.
By regularly recording the late effects over a long period of time, the toxicity of future studies can be reduced by adapting the therapy.
The patients are written to directly; they receive a questionnaire approximately every three years.

All patients who had been treated within a German-Austrian Morbus Hodgkin trial for children and adolescents